ITOX.OTC.PinkIiot-oxys, INC

10-K: IIOT-OXYS Converts Debt to Equity, Reports Mixed Financial Results in 2023

Sentiment:

Annual Results


IIOT-OXYS executed a debt exchange agreement, converting a significant portion of debt into equity, while also reporting increased revenues but continued net losses for 2023.

Capital raiseThe company has an existing Equity Financing Agreement with GHS Investments, LLC, which allows for the sale of up to $2,500,000 worth of common stock.The company has been selling shares under this agreement, but the proceeds have not been sufficient to cover operating losses.The company is considering additional capital raising options, including potential mergers or acquisitions.
Worse than expectedThe company's net loss increased in 2023 compared to 2022, indicating worsening financial performance.The company's cash balance decreased significantly, raising concerns about its ability to fund operations.The company's management has expressed substantial doubt about its ability to continue as a going concern.

Summary

  • IIOT-OXYS, Inc. entered into a debt exchange agreement on February 5, 2024, with Cambridge MedSpace LLC, converting $68,825 of debt into 57 shares of Series C Preferred Stock.
  • The company's 2023 revenue increased to $114,666, up from $88,904 in 2022, but cost of sales also increased to $76,645.
  • Operating expenses for 2023 were $731,430, including significant professional fees, payroll costs, and bad debts.
  • The company reported a net loss of $1,136,460 for 2023, compared to a net loss of $1,076,881 in 2022.
  • The company's cash balance decreased to $644 at the end of 2023, down from $33,336 at the end of 2022.
  • The company has a working capital deficit of $2,067,461 and an accumulated deficit of $10,443,597 as of December 31, 2023.
  • Management acknowledges substantial doubt about the company's ability to continue as a going concern due to ongoing losses and limited funding.

Sentiment

Score: 3

Explanation: The document reveals a company with some positive revenue growth but significant financial challenges, including substantial losses, low cash reserves, and doubts about its ability to continue as a going concern. The debt conversion is a positive step, but the overall outlook is concerning from an investment perspective.

Positives

  • The company's revenue increased by 29% in 2023 compared to 2022.
  • The company successfully converted a portion of its debt into equity, potentially improving its balance sheet.
  • The company is seeing traction in the structural health monitoring and smart manufacturing industries.
  • The company has strategic partnerships that could lead to accelerated growth.

Negatives

  • The company experienced a net loss of $1,136,460 in 2023.
  • The company's cash balance is critically low at $644.
  • The company has a significant working capital deficit of $2,067,461.
  • The company has an accumulated deficit of $10,443,597.
  • The company's management has expressed substantial doubt about its ability to continue as a going concern.
  • The company has material weaknesses in its internal control over financial reporting.

Risks

  • The company's ability to continue as a going concern is in doubt due to ongoing losses and limited funding.
  • The company has material weaknesses in its internal control over financial reporting.
  • The company faces significant competition from larger companies and startups in the IIoT space.
  • The company's ability to raise funds for sales and marketing efforts is limited.
  • The company is dependent on a few major customers, which poses a risk to revenue stability.
  • The company's CEO and COO have not received compensation since mid-April, which may impact operations.

Future Outlook

The company expects moderate revenue growth in 2024 due to limited ability to raise funds for sales and marketing efforts. Potential future revenue growth is possible, pending adequate funding for sales and marketing efforts. Management is also pursuing options including vetting suitable companies to merge with or acquire them.

Management Comments

  • Management believes that the company will be able to achieve a satisfactory level of liquidity to meet the company's obligations for the next 12 months by generating cash through additional borrowings and/or sale of equity securities, as needed.
  • Management acknowledges substantial doubt about the company's ability to continue as a going concern due to ongoing losses and limited funding.
  • Management is working to secure funding from our lead investor to pay for ongoing expenses and the leadership team is considering its options for both the short and long term.

Industry Context

The company operates in the growing markets of smart manufacturing (Industry 4.0) and structural health monitoring (SHM). The global smart manufacturing market is projected to reach $241 billion by 2028, and the worldwide SHM industry is expected to reach $4.1 billion by 2029. The company's focus on edge computing and advanced algorithms positions it to capitalize on these trends.

Comparison to Industry Standards

  • The company's revenue growth of 29% in 2023 is a positive sign, but its continued net losses and low cash balance are concerning when compared to industry benchmarks for early-stage technology companies.
  • While the company is targeting high-growth markets, its financial performance lags behind many competitors who have secured more substantial funding and achieved greater market penetration.
  • The company's reliance on a few major customers is a risk, as many successful startups diversify their customer base to mitigate revenue volatility.
  • The company's internal control weaknesses are a significant concern, as most publicly traded companies are expected to have robust financial controls.
  • Compared to companies like Siemens, PTC, IBM, GE, Amazon, and Google, who are also in the IIoT space, IIOT-OXYS is significantly smaller and has fewer resources. Startups like FogHorn Systems Inc., Tulip Interfaces, and MachineSense are more comparable in size but may have stronger financial backing.

Related Party Transactions

  • The company entered into a debt exchange agreement with Cambridge MedSpace LLC, an entity of which the company's CEO shares ownership.
  • The company has convertible notes payable to Vidhyadhar Mitta, a director of the company.
  • The company leases its office facility from stockholders on a month-to-month basis.

Stakeholder Impact

  • Shareholders face significant risk due to the company's financial instability and potential for dilution.
  • Employees face uncertainty due to the company's financial challenges and potential for restructuring.
  • Customers may be concerned about the company's ability to continue providing services.
  • Creditors face risk of non-payment due to the company's low cash balance and high debt levels.

Next Steps

  • The company will continue to pursue sales and marketing efforts, focusing on its current DOT Bridge Monitoring Contract and CNC SaaS contract.
  • The company will continue to develop strategic partnerships to expand its market reach.
  • The company will seek additional funding through borrowings, equity sales, or potential mergers or acquisitions.
  • The company will work to remediate material weaknesses in its internal control over financial reporting.

Key Dates

DateDescription
2003-10-01Company incorporated in New Jersey as Creative Beauty Supply of New Jersey Corporation.
2004-01-01Company commenced operations in the beauty supply industry.
2007-11-30Board of Directors approved a plan to dispose of the wholesale and retail beauty supply business.
2009-01-01Company had no operations and was a shell company until July 28, 2017.
2016-08-04OXYS Corporation incorporated in Nevada.
2017-03-16Board of Directors adopted resolutions to change name to IIOT-OXYS, Inc., change domicile to Nevada, authorize a 2017 Stock Awards Plan, and approve the Securities Exchange Agreement with OXYS Corporation.
2017-07-28OXYS SEA was effective, and the company's name was changed to IIOT-OXYS, Inc.
2017-10-26Company's domicile was changed from New Jersey to Nevada.
2018-02-05Company entered into a Non-Exclusive Patent License Agreement with MIT.
2018-08-01Company entered into a yearly lease agreement for its principal office in Cambridge, Massachusetts.
2018-10-31Company sent written notice of intent to terminate the agreement with MIT.
2018-12-06Company received a notice of termination from MIT due to non-payment of fees.
2019-01-22Company entered into a Securities Purchase Agreement with Cambridge MedSpace, LLC.
2019-03-11Board of Directors adopted the 2019 Stock Incentive Plan.
2019-08-02Company entered into a Securities Purchase Agreement with Vidhyadhar Mitta.
2020-07-02Board of Directors authorized issuance of Series A Supervoting Preferred Stock.
2020-11-16Board of Directors authorized issuance of Series B Convertible Preferred Stock.
2021-11-01Company entered into an Equity Financing Agreement with GHS Investments, LLC.
2022-03-18Board of Directors adopted the 2022 Stock Incentive Plan.
2022-04-04Company issued an unsecured convertible promissory note with a principal sum of $200,000.
2022-06-02Board of Directors approved Employment Contracts with Clifford Emmons and Karen McNemar.
2023-08-24Company entered into a new preferred equity financing agreement with GHS Investments, LLC.
2024-02-05Company entered into a Debt Exchange Agreement with Cambridge MedSpace LLC.

Keywords

IIOT-OXYS, debt exchange, equity financing, convertible preferred stock, financial results, net loss, revenue growth, edge computing, smart manufacturing, structural health monitoring, internal control, going concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.